← FDA DRUG APPROVALS

FDA ANDA · ANDA205301

ACETAZOLAMIDE

Sponsor: CADILA

APPLICATION
ANDA205301
TYPE
ANDA
ORIGINAL APPROVAL
2019-01-16
LATEST ACTION
2024-11-26
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

ACETAZOLAMIDEPrescription
ACETAZOLAMIDE 500MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2024-11-26Labeling · Supplement 5 · standardAP
2023-09-14Labeling · Supplement 3 · standardAP
2019-01-16UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →